Damora Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GLTO research report →
Range $10 – $46
Price Chart
About the company
Damora Therapeutics, Inc. , a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.
- CEO
- Jennifer A. Jarrett
- IPO
- 2020
- Employees
- 7
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on GLTO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $34.47M
- P/E
- -0.16
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 2.32
- EV/EBITDA
- -2.49
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -82.56%
- ROIC
- -52.44%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-34,000+0.0%
- Op Income
- $-210,872,000
- Net Income
- $-209,839,000-878.8%
- EPS
- $-152.99-725.6%
- OCF Growth
- +63.9%
- FCF Growth
- +63.9%
- 52W High
- $38.33
- 52W Low
- $2.01
- 50D MA
- $26.12
- 200D MA
- $13.34
- Beta
- 1.60
- RSI (14)
- 43
- Avg Volume
- 480.39K
No earnings-call transcripts are available for GLTO yet.
- Free Float
- 92.4%
- Shares Outstanding
- 1.60M
- Float Shares
- 1.48M
of shares held by institutions
26 13F filers
Buy/sell ratio 0.83. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 21.20K | ▼ 29.82K |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 9, 26 | Bruno Julianne | other | 129,000 |
| Feb 9, 26 | Bruno Julianne | other | 129 |
| Feb 9, 26 | Fairmount Funds Management LLC | other | 5,809,000 |
| Feb 9, 26 | Fairmount Funds Management LLC | other | 2,904,000 |
| Feb 9, 26 | Fairmount Funds Management LLC | other | 5,809 |
| Feb 9, 26 | Fairmount Funds Management LLC | other | 2,904 |
| Jan 5, 26 | Sattarzadeh Sherwin | other | 444,209 |
| Jan 5, 26 | Sattarzadeh Sherwin | other | 190,376 |
| Jan 5, 26 | Sattarzadeh Sherwin | other | 0 |
| Jan 5, 26 | Hewes L. Becker | other | 528,603 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GLTO coverage
Recent articles, reports, and earnings notes.
No research on GLTO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GLTO report →What Makes Galecto, Inc. (DMRA) a Strong Momentum Stock: Buy Now?
zacks.com · Apr 20
Galecto, Inc. (NASDAQ:GLTO) Given Consensus Recommendation of “Moderate Buy” by Brokerages
defenseworld.net · Mar 4
Galecto, Inc. (NASDAQ:GLTO) Short Interest Up 86.6% in February
defenseworld.net · Mar 2
Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million
globenewswire.com · Feb 12
Galecto Announces Pricing of $275 Million Underwritten Public Offering
globenewswire.com · Feb 10
Galecto, Inc. (NASDAQ:GLTO) Given Average Rating of “Moderate Buy” by Analysts
defenseworld.net · Jan 18
Analysts Set Galecto, Inc. (NASDAQ:GLTO) PT at $41.00
defenseworld.net · Jan 16
Comparing Galecto (NASDAQ:GLTO) and Avidity Biosciences (NASDAQ:RNA)
defenseworld.net · Jan 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.